Generalized Myasthenia Gravis Clinical Trials in London
8 recruitingLondon, United Kingdom
Showing 1–8 of 8 trials
Recruiting
Phase 2Phase 3
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Myasthenia GravisGeneralized Myasthenia Gravis
Kyverna Therapeutics66 enrolled22 locationsNCT06193889
Recruiting
Phase 2Phase 3
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
UCB Biopharma SRL8 enrolled9 locationsNCT06055959
Recruiting
Phase 1Phase 2
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Novartis Pharmaceuticals15 enrolled11 locationsNCT06704269
Recruiting
Phase 3
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Generalized Myasthenia Gravis
Novartis Pharmaceuticals146 enrolled125 locationsNCT06517758
Recruiting
Phase 3
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Immunovant Sciences GmbH231 enrolled84 locationsNCT07039916
Recruiting
Phase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Novartis Pharmaceuticals180 enrolled129 locationsNCT06744920
Recruiting
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
PregnancyParoxysmal Nocturnal Hemoglobinuria, PNHUltomiris-exposed Pregnant/ Postpartum+3 more
Alexion Pharmaceuticals, Inc.75 enrolled7 locationsNCT06312644
Recruiting
Phase 2Phase 3
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
argenx12 enrolled25 locationsNCT04833894